News & Updates

Show Multimedia Only

Objective response to systemic therapy linked to overall survival in unresectable HCC

23 Jan 2023 by

Objective response to first-line systemic therapy with lenvatinib or sorafenib independently predicts overall survival (OS) in individuals with unresectable hepatocellular carcinoma (HCC), as shown by the subanalysis of the REFLECT study.

23 Jan 2023

Idiopathic/local factor NC-SVT ups risk of recurrent thrombosis

19 Jan 2023

The risk of overall recurrent thrombosis (RT) is greater among individuals with idiopathic/local factor-related noncirrhotic splanchnic vein thrombosis (NC-SVT), reveals a study. Moreover, splanchnic RT can appear without symptoms and requires screening to be detected.

19 Jan 2023

START-FIT: TACE + RT + avelumab promising as conversion therapy for locally advanced unresectable HCC

18 Jan 2023 by

START-FIT, a prospective, single-arm, phase II trial, has found sequential transarterial chemoembolization (TACE) and stereotactic body radiotherapy (SBRT) followed by anti–PD-L1 treatment with avelumab to be a promising strategy for making patients with locally advanced unresectable hepatocellular carcinoma (HCC) amenable to curative treatment.

18 Jan 2023

Elevated homocysteine level tied to higher NAFLD risk

14 Jan 2023

Circulating homocysteine and folate concentrations appear to play a significant role in the development of nonalcoholic fatty liver disease (NAFLD), a study has shown.

14 Jan 2023

NAFLD screening a cost-effective approach among T2DM patients in SG

12 Jan 2023 by

Nonalcoholic fatty liver disease (NAFLD) screening strategies, particularly vibration-controlled transient elastography (VCTE) and fibrosis-4 (FIB-4), are a cost-effective approach to reduce disease burden among type 2 diabetes mellitus (T2DM) patients in Singapore, according to a study.

12 Jan 2023

Corticosteroid poses no excess mortality risk in drug-induced liver injury

09 Jan 2023

Treatment with corticosteroid in patients with drug-induced liver injury (DILI) does not appear to contribute to increased risk of death but rather helps normalize liver enzymes, as shown in a study.

09 Jan 2023

Albumin confers survival benefit in select patients with cirrhosis

31 Dec 2022

Treatment with albumin appears to cut the risk of death in cirrhotic patients with spontaneous bacterial peritonitis or hepatic encephalopathy, with long-term treatment potentially lowering the risk of cirrhosis complications and need for paracentesis, according to the results of a meta-analysis.

31 Dec 2022

TACE + apatinib: A potential new strategy for intermediate/advanced HCC?

28 Dec 2022 by

In patients with intermediate or advanced hepatocellular carcinoma (HCC), combining transarterial chemoembolization (TACE) with apatinib led to improvement in progression-free survival (PFS), according to a recent study from China.